Missed dose: difference between revisions
Diff·revision 8 → 9·08:20, 7 Feb 2025
Difference between revision 8 and revision 9 of Missed dose. 11 lines changed; the page grew by 736 bytes.
| Revision 8 — 11:09, 16 Jan 2025 RotationRosalind (talk) state that reconstituted material should not be frozen, with the source 3,387 bytes +32 | Revision 9 — 08:20, 7 Feb 2025 Chromatokid (talk) rm the individualised advice — the article describes, it does not instruct 4,123 bytes +736 | ||
|---|---|---|---|
| 27 | Re-escalation after a longer interruption is a tolerability question rather than an efficacy one: gastrointestinal tolerance to these agents is partly adaptive, and adaptation is lost over a sufficiently long gap. | 27 | Re-escalation after a longer interruption is a tolerability question rather than an efficacy one: gastrointestinal tolerance to these agents is partly adaptive, and adaptation is lost over a sufficiently long gap. |
| 28 | 28 | ||
| + | 29 | == What product labelling addresses == | |
| + | 30 | Labelling for weekly incretin products typically permits a missed dose to be taken within a defined window and otherwise omitted, with the next dose taken on the regular schedule; and it typically addresses changing the day of the week, which is possible when the half-life is long.{{r|drucker2018}} | |
| + | 31 | ||
| + | 32 | The windows differ between products because the half-lives differ, which is why a rule learned for one product does not transfer to another. This is a specific instance of the general point that class membership does not imply interchangeability. See [[GLP-1 receptor agonist]]. | |
| + | 33 | ||
| 29 | == References == | 34 | == References == |
| 30 | {{reflist}} | 35 | {{reflist}} |
| ⋮ | ⋮ | ||
| 33 | <ref name="ada2024">American Diabetes Association. "Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 38 | <ref name="ada2024">American Diabetes Association. "Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| 34 | <ref name="lau2015">Lau J, Bloch P, Schäffer L, et al. "Discovery of the once-weekly glucagon-like peptide-1 analog semaglutide." ''Journal of Medicinal Chemistry'' 58(18):7370–7380 (2015). PMID 26308095.</ref> | 39 | <ref name="lau2015">Lau J, Bloch P, Schäffer L, et al. "Discovery of the once-weekly glucagon-like peptide-1 analog semaglutide." ''Journal of Medicinal Chemistry'' 58(18):7370–7380 (2015). PMID 26308095.</ref> |
| + | 40 | ||
| + | 41 | == See also == | |
| + | 42 | * [[Dose escalation schedule]] | |
| + | 43 | * [[Dose titration]] | |
| + | 44 | * [[Prescribing information]] | |
| + | 45 | * [[Semaglutide]] | |
| 35 | 46 | ||
| 36 | {{DEFAULTSORT:Missed dose}} | 47 | {{DEFAULTSORT:Missed dose}} |